Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:53 PM
Ignite Modification Date:
2025-12-24 @ 10:53 PM
NCT ID:
NCT05941169
Eligibility Criteria:
Inclusion Criteria:
1. Male or female patients age ≥ 18 years
2. Signed and written informed consent Note: Written and signed informed consent will be obtained before any study procedures, including study-specific-screening procedures, has been performed.
3. Informed consent obtained for being offered future experimental interventions within the PRO-RCC project.
4. Histologically confirmed diagnosis of metastatic clear cell, papillary or chromophobe renal cell carcinoma of intermediate to poor risk, including sarcomatoid features, with
5. World Health Organization (WHO) performance status of 0-1.
6. Surgical candidates based on surgeon and anesthetist assessment
7. Treatment with an IO combination (IO+IO or IO+TKI) as standard of care for metastatic RCC
8. Absence of progression at metastatic sites at time of identification (6month after start of systemic first line treatment). 9) Primary tumor in situ 10) Participation in the PRO-RCC prospective cohort.
Exclusion Criteria:
NA
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05941169
Study Brief:
Protocol Section:
NCT05941169